Investigational drug · Phase 2
IAP0971
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Malignant Neoplasm, Advanced or Metastatic Non-small Cell Lung Cancer, Bladder Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Jan 15, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
4
Any phase or sponsor naming "IAP0971"
First trial start
2024
Feb 15, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "IAP0971", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Malignant Neoplasm
- Advanced or Metastatic Non-small Cell Lung Cancer
- Bladder Cancer
- Advanced Malignant Tumors
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Bladder and urothelial cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "IAP0971" as an intervention, largest first.
- A Study of IAP0971 in Combination With Bacillus Calmette Guerin in High Risk Non-muscular Invasive Bladder CancerNot yet recruiting
SUNHO(China)BioPharmaceutical CO., Ltd.Industry
NCT06255964 · 236 participants (planned) · Start Feb 15, 2024 · Primary completion Oct 7, 2024
Drug: IAP0971 · For: Bladder Cancer
- A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant TumorsStatus unknown
SUNHO(China)BioPharmaceutical CO., Ltd.Industry
NCT05396391 · 140 participants (planned) · Start Jun 22, 2022 · Primary completion May 30, 2024
Drug: IAP0971 · For: Advanced Malignant Tumors
Sites: Shanghai, China
SUNHO(China)BioPharmaceutical CO., Ltd.Industry
NCT06581419 · 78 participants (planned) · Start Dec 31, 2024 · Primary completion Aug 1, 2029
Drug: IAP0971 · For: Advanced Malignant Neoplasm; Advanced or Metastatic Non-small Cell Lung Cancer
Sites: Beijing, China
SUNHO(China)BioPharmaceutical CO., Ltd.Industry
NCT06223841 · 50 participants (planned) · Start Mar 1, 2024 · Primary completion Mar 1, 2026
Drug: IAP0971 · For: Advanced Malignant Tumors
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
- Preclinical evaluation of IAP0971, a novel immunocytokine that binds specifically to PD1 and fuses IL15/IL15Rα complex.
Chen J, Shen Z, Jiang X, et al. · Antib Ther 2023
Also in development for Advanced Malignant Neoplasm
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.